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Protein tyrosine phosphatase N2 regulates TNFα-induced
signalling and cytokine secretion in human intestinal epithelial
cells
Abstract
Objective The Crohn's disease (CD) susceptibility gene, protein tyrosine phosphatase N2 (PTPN2),
regulates interferon γ (IFNγ)-induced signalling and epithelial barrier function in T(84) intestinal
epithelial cells (IECs). The aim of this study was to investigate whether PTPN2 is also regulated by
tumour necrosis factor α (TNFα) and if PTPN2 controls TNFα-induced signalling and effects in IECs.
Methods T(84) IECs were used for all cell studies. Protein levels were assessed by western blotting,
mRNA levels by reverse transcription-PCR (RT-PCR) and cytokine levels by ELISA. PTPN2
knock-down was induced by small interfering RNA (siRNA). Imaging was performed by
immunohistochemistry or immunofluorescence. Results TNFα treatment elevated PTPN2 mRNA as
well as nuclear and cytoplasmic protein levels and caused cytoplasmic accumulation of PTPN2. Biopsy
specimens from patients with active CD showed strong immunohistochemical PTPN2 staining in the
epithelium, whereas samples from patients with CD in remission featured PTPN2 levels similar to
controls without inflammatory bowel disease (IBD). Though samples from patients with active
ulcerative colitis (UC) revealed more PTPN2 protein than non-IBD patients and patients with UC in
remission, their PTPN2 expression was lower than in active CD. Samples from patients with CD in
remission and responding to anti-TNF treatment also showed PTPN2 levels that were similar to those in
control patients. Pharmacological inhibition of nuclear factor-κB (NF-κB) by BMS-345541 prevented
the TNFα-induced rise in PTPN2 protein, independent of apoptotic events. PTPN2 knock-down
revealed that the phosphatase regulates TNFα-induced extracellular signal-regulated kinase 1/2
(ERK1/2) and p38 phosphorylation, without affecting c-Jun N-terminal kinase (JNK), inhibitor of κB
(IκB) or NF-κB phosphorylation. Loss of PTPN2 potentiated TNFα-induced secretion of interleukin 6
(IL-6) and IL-8. In TNFα- and IFNγ-co-treated cells, loss of PTPN2 enhanced protein expression of
inducible nitric oxide synthase (iNOS). Conclusions TNFα induces PTPN2 expression in IECs. Loss of
PTPN2 promotes TNFα-induced mitogen-activated protein kinase signalling and the induction of
inflammatory mediators. These data indicate that PTPN2 activity could play a crucial role in the
establishment of chronic inflammatory conditions in the intestine, such as CD.
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Protein tyrosine phosphatase N2 regulates
TNFa-induced signalling and cytokine secretion in
human intestinal epithelial cells
Michael Scharl,1 Declan F McCole,2 Achim Weber,3 Stephan R Vavricka,1
Pascal Frei,1 Silvia Kellermeier,1 Theresa Pesch,1 Michael Fried,1 Gerhard Rogler1
ABSTRACT
Objective The Crohn’s disease (CD) susceptibility gene,
protein tyrosine phosphatase N2 (PTPN2), regulates
interferong (IFNg)-induced signalling and epithelial barrier
function in T84 intestinal epithelial cells (IECs). The aim of
this study was to investigate whether PTPN2 is also
regulated by tumour necrosis factora (TNFa) and if PTPN2
controls TNFa-induced signalling and effects in IECs.
Methods T84 IECs were used for all cell studies. Protein
levels were assessed by western blotting, mRNA levels
by reverse transcriptionePCR (RTePCR) and cytokine
levels by ELISA. PTPN2 knock-down was induced by
small interfering RNA (siRNA). Imaging was performed
by immunohistochemistry or immunofluorescence.
Results TNFa treatment elevated PTPN2 mRNA as well
as nuclear and cytoplasmic protein levels and caused
cytoplasmic accumulation of PTPN2. Biopsy specimens
from patients with active CD showed strong
immunohistochemical PTPN2 staining in the epithelium,
whereas samples from patients with CD in remission
featured PTPN2 levels similar to controls without
inflammatory bowel disease (IBD). Though samples from
patients with active ulcerative colitis (UC) revealed more
PTPN2 protein than non-IBD patients and patients with
UC in remission, their PTPN2 expression was lower than
in active CD. Samples from patients with CD in remission
and responding to anti-TNF treatment also showed
PTPN2 levels that were similar to those in control
patients. Pharmacological inhibition of nuclear factor-kB
(NF-kB) by BMS-345541 prevented the TNFa-induced
rise in PTPN2 protein, independent of apoptotic events.
PTPN2 knock-down revealed that the phosphatase
regulates TNFa-induced extracellular signal-regulated
kinase 1/2 (ERK1/2) and p38 phosphorylation, without
affecting c-Jun N-terminal kinase (JNK), inhibitor of kB
(IkB) or NF-kB phosphorylation. Loss of PTPN2
potentiated TNFa-induced secretion of interleukin 6
(IL-6) and IL-8. In TNFa- and IFNg-co-treated cells, loss
of PTPN2 enhanced protein expression of inducible nitric
oxide synthase (iNOS).
Conclusions TNFa induces PTPN2 expression in IECs.
Loss of PTPN2 promotes TNFa-induced mitogen-activated
protein kinase signalling and the induction of inflammatory
mediators. These data indicate that PTPN2 activity
could play a crucial role in the establishment of chronic
inflammatory conditions in the intestine, such as CD.
INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC)
represent two subtypes of chronic intestinal
inflammation and are collectively referred to as
inflammatory bowel disease (IBD). The pathogen-
esis of IBD includes genetic, immunological and
bacterial factors. There is evidence that a genetic
predisposition favours a prominent role for an
epithelial barrier defect in the onset of disease.1 As
a result of increased access to the lamina propria,
commensal bacteria cause an overwhelming acti-
vation of the immune system, which isddue to
genetic mutations in regulatory genesdout of
control and thus amplifies the inflammatory state.2
Intestinal epithelial cells (IECs) form a primary
barrier against luminal antigens and toxins, and
contribute to the regulation of essential intestinal
immune responses, such as antigen presentation to
immune cells or cytokine production. Especially in
CD, an increased rate of IEC apoptosis can be
observed that may exacerbate the barrier defect
and increase the passage of antigens through the
intestinal epithelium.3 4
During IBD, the levels of proinflammatory
cytokines are highly elevated, whereas the secretion
or activity of anti-inflammatory mediators is
< Additional methods are
published online only. To view
these files please visit the
journal online (http://gut.bmj.
com).
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Significance of this study
What is already known about this subject?
< A mutation within the gene locus encoding
PTPN2 is associated with IBD.
< PTPN2 regulates IFNg-induced STAT signalling
in intestinal epithelial cells.
< PTPN2 restricts the IFNg-induced barrier defect
in intestinal epithelial cells.
What are the new findings?
< PTPN2 expression is increased by TNFa in
intestinal epithelial cells and elevated in active
CD.
< PTPN2 regulates TNFa-induced MAPK signalling.
< PTPN2 regulates TNFa-induced cytokine
secretion.
How might it impact on clinical practice in the
foreseeable future?
< These data show that PTPN2 is activated by
TNFa in intestinal epithelial cells and regulates
TNFa-induced signalling and cytokine secretion.
These findings suggest a possible mechanism to
explain how dysfunction of PTPN2 could
contribute to the onset of chronic intestinal
inflammation, such as Crohn’s disease.
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strongly impaired.5 Both UC and CD are characterised by their
specific cytokine profile, and elevated levels of tumour necrosis
factor a (TNFa) are well established as critical events in IBD,
most prominently in CD.6
TNFa can cause proliferation, differentiation, inflammation or
cell death depending on the specific cell type and the cellular
signalling milieu.7 The key regulatory factor dictating the
specific cellular responses to TNFa is the balance in the activa-
tion of TNFa-induced signalling pathways.8 TNFa binding to its
ubiquitously expressed type 1 TNF receptor (TNFR1) can result
in the recruitment of inhibitor of kB (IkB) kinase (IKK).9
Recruited IKK targets IkB for degradation, and the released
transcription factor, nuclear factor-kB (NF-kB), can translocate
into the nucleus to initiate gene transcription.7 On the other
hand, TNFa signalling can also lead to the activation of
mitogen-activated protein kinase (MAPK) isoforms p38, extra-
cellular signal-regulated kinases 1 and 2 (ERK1/2) and c-Jun
N-terminal kinase (JNK), resulting mainly in the activation of
the transcription factor, activator protein 1 (AP-1).7 10 Among
the TNFa-inducible genes are important proinflammatory
mediators such as the interleukins IL-6 and IL-8, as well as the
inducible nitric oxide synthase (iNOS). Additionally, TNFa can
trigger the activation of certain caspases, especially caspase-3
and caspase-7, that are crucial for the induction of apoptosis.11
TNFa antibodies have been shown to reduce inflammation and
IEC apoptosis in patients with active CD by in vivo adminis-
tration12 13 and are a mainstay of treatment for refractory CD14
and UC.15
Important new avenues of investigation into the pathogenesis
of IBD have been directed by genome-wide association studies
that identified a number of disease-associated candidate genes.
One of those genes, protein tyrosine phosphatase non-receptor
type 2 (PTPN2), has recently been associated with CD and
UC.16 17 PTPN2, also known as T cell protein tyrosine phos-
phatase (TC-PTP), exists in a nuclear 45 kDa and a cytoplasmic
48 kDa isoform. Following its activation, the catalytically more
important nuclear isoform can exit the nucleus and accumulate
in the cytoplasm.18 In various cell types, PTPN2 inactivates
important immune mediatorsdthat is, signal transducer and
activator of transcription 1 (STAT1)19 and STAT320das well as
p38 and ERK1/2,21 and has also been implicated in the regula-
tion of apoptosis in pancreatic b cells.22 Of special interest with
respect to CD is that PTPN2 regulates intestinal epithelial
barrier function, thus identifying a novel link between a disease-
associated gene and a key pathophysiological event in CD.23
A role for PTPN2 in regulating TNFa-induced signalling and
function in IECs has not yet been studied. We demonstrate that
PTPN2 is activated by TNFa via NF-kB and regulates TNFa-
induced MAPK signalling. From a functional perspective, loss of
PTPN2 results in increased levels of proinflammatory mediators
and correlates with elevated numbers of apoptotic events in
IECs. These data identify PTPN2 as a key regulator of TNFa
effects in IECs and further emphasise a potential role for PTPN2
in the pathogenesis of CD.
MATERIALS AND METHODS
Material
Human TNFa (Promokine, Heidelberg, Germany), human inter-
feron g (IFNg; Promokine), BMS-345541 (Sigma, St. Louis,
Missouri, USA), rabbit antilamin A/C (BD Biosciences, San Jose,
California, USA), mouse anti-b-actin (Sigma), mouse anti-PTPN2
(Calbiochem, SanDiego, California, USA) and rabbit anti-ERK1/2
antibodies (Santa Cruz, Santa Cruz, California, USA) were
obtained from the sources noted. Rabbit antiphospho-ERK1/2
(Thr202/Tyr204), rabbit anti-p38, mouse antiphospho-p38
(Thr180/Tyr182), rabbit anti-JNK, rabbit anti-phospho-JNK
(Thr183/Tyr185), rabbit anti-p65-NF-kB, rabbit antiphospho-
p65-NFkB (Ser536), rabbit anti-IkBa, rabbit antiphospho-IkBa
(Ser32) and rabbit anti-iNOS antibodies were obtained from Cell
Signalling Technologies (Danvers, Massachusetts, USA). Rabbit
anticaspase-3 antibody (Cell Signaling) detected both full-length
and cleaved protein variants. All other reagents were of analytical
grade and were acquired commercially.
Cell culture
Human colonic crypt T84 epithelial cells were cultured in
a humidified atmosphere with 10% CO2 in 4.5% high glucose
Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad,
California, USA) supplemented with 10% newborn calf serum.
Cells were separated by trypsinisation and 13106 cells were
seeded onto either 12 mm or 30 mm Millicell-HA semi-perme-
able filter supports (Millipore, Bedford, Massachusetts, USA).
Cells used for experiments were between passage 21 and 32.
Before treatment, cells were cultured for 8e14 days, and trans-
epithelial electrical resistance was measured to ensure intact
monolayers. According to their receptor localisation, TNFa
(100 ng/ml) and IFNg (100 ng/ml) were added basolaterally,
while BMS-345541 (25 mM) was added bilaterally.
Patient samples
Tissue specimens were prospectively collected from the colon of
male and female non-IBD control patients who were asymp-
tomatic and presented for colon cancer screening (n¼11; average
age: 5664 years), from male and female patients with clinically
and macroscopically active CD (n¼16; average age: 4563 years),
from male and female patients with CD clinically and macro-
scopically in remission (n¼10; average age: 4264 years), from
male and female patients with clinically and macroscopically
active UC (n¼11; average age: 3765 years), from male and
female patients with UC clinically and macroscopically in
remission (n¼10; average age: 4264 years) and from male and
female patients with clinically and macroscopically inactive CD
(n¼4) receiving anti-TNF treatment (average age: 5664 years).
Histological assessment of active or inactive disease was
performed by a pathologist. Tissue samples were immediately
transferred into 4% formalin and stored at 48C until further
analysis. Written informed consent was obtained before spec-
imen collection, and studies were approved by the Cantonal
Ethics Committee of the Canton of Zurich.
Histological PTPN2 score
Protein levels of PTPN2 in the investigated biopsy tissue speci-
mens were analysed by a pathologist in a blinded fashion. The
following scoring system was used for evaluating PTPN2 levels:
0¼PTPN2 protein not detectable; 1¼PTPN2 protein poorly
detectable; 2¼PTPN2 protein obviously detectable; 3¼PTPN2
protein heavily expressed. All of the studied samples were
evaluated.
RNA isolation and real-time PCR
RNA analysis, primer sequences and PCR conditions are
described in the supplementary methods.
Preparation of whole-cell lysates
Whole-cell lysates were generated using M-Per Mammalian
protein extraction reagent (Pierce Biotechnology, Rockford, Illi-
nois, USA) according to the manufacturer ’s instructions and as
described in the supplementary methods.
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Preparation of cytoplasmic and nuclear lysates
Separate cytoplasmic and nuclear lysates were obtained using
a Nuclear Extract Kit (Active Motif, San Diego, California, USA)
according to the manufacturer ’s instructions and as described in
the supplementary methods.
Western blotting
Experimental procedures are described in detail in the supple-
mentary methods.
Immunofluorecence microscopy
A total of 53105 T84 cells were seeded onto 12 mm Millicell-HA
filters for 2 (small interfering RNA (siRNA)-transfected cells) to
6 days before stimulation. Experimental conditions and staining
protocols are described in detail in the supplementary methods.
Immunhistochemistry
Immunhistochemical studies were performed on tissue speci-
mens using a peroxidase-based method with diaminobenzidine
(DAB) chromogen (DAKO, Glostrup, Denmark) as described
previously.24 Experimental conditions and staining protocols are
described in detail in the supplementary methods.
siRNA transfection
Experimental conditions and oligonucleotide sequences are
described in the supplementary methods.
ELISA
Experimental procedures are described in the supplementary
methods.
Statistical analysis
Data are presented as means6SEM for a series of n experiments.
Data are expressed as a percentage of the respective control.
Statistical analysis was performed by analysis of variance
(ANOVA) followed by StudenteNewmaneKeuls post hoc test.
p Values <0.05 were considered significant.
RESULTS
TNFa increases PTPN2 expression in T84 IECs
To identify the maximally effective dose of TNFa capable of
inducing PTPN2 protein expression in T84 IECs, we stimulated
these cells with 1, 10 or 100 ng/ml TNFa for 24 h. As shown by
representative western blots and densitometric analysis, 10 ng/
ml TNFa significantly induced PTPN2 protein expression, and
this effect was further enhanced by 100 ng/ml TNFa (figure 1A).
Based on this observation, we continued with a concentration of
100 ng/ml TNFa in all of our subsequent experiments. We next
studied whether TNFa could elevate PTPN2 mRNA levels. We
treated T84 cells for 2, 8, 16, 24, 48 and 72 h, and TNFa increased
PTPN2 mRNA levels significantly after 8 and 48 h incubations
(figure 1B).
We then tested whether TNFa could affect PTPN2 protein
expression at different time points. We collected separate cyto-
plasmic and nuclear protein lysates from T84 cells after TNFa
treatment for 24, 48 and 72 h. In the nuclear compartment,
TNFa increased PTPN2 protein by 24 h. Although PTPN2
protein was elevated after 48 h treatment, these levels were not
statistically significantly above control values. After 72 h of
TNFa stimulation, nuclear PTPN2 protein levels had reached
controls levels again (figure 1C). In contrast, TNFa did not
affect cytoplasmic PTPN2 protein by treatment for 24 and
48 h. However, after 72 h TNFa stimulation, PTPN2 protein
was significantly elevated in the cytoplasmic compartment
(figure 1D). These data demonstrate that TNFa induces PTPN2
mRNA as well as protein expression in T84 IECs.
TNFa causes cytoplasmic accumulation of PTPN2 in T84 IECs
The different pattern of PTPN2 protein expression in the
different cell compartments in response to TNFa suggests that
Figure 1 Tumour necrosis factor
a (TNFa) increases expression levels
and affects cellular localisation of
protein tyrosine phosphatase N2
(PTPN2) in T84 cells. (A) PTPN2 protein
in whole-cell lysates derived from
TNFa-treated (24 h) T84 cells shown by
representative western blots of PTPN2
and the loading control, b-actin. The
relative protein level was assessed by
densitometric analysis (n¼4). (B)
PTPN2 mRNA expression in response to
TNFa, normalised to glyceraldehyde
phosphate dehydrogenase (GAPDH).
Four similar experiments were
performed, each in triplicate. (C)
Nuclear PTPN2 protein in TNFa-treated
T84 cells shown by representative
western blots. Lamin A/C was used as
a loading control (n¼4). (D)
Cytoplasmic PTPN2 protein in
TNFa-treated T84 cells is demonstrated
by representative western blots and
densitometric analysis (n¼4). b-Actin
was used as a loading control. Asterisks
denote significant differences from the
respective control (*p<0.05;
**p<0.01; ***p<0.001). #p<0.05;
##p<0.01; ###p<0.001 vs 72 h
TNFa treatment.
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TNFa could affect the intracellular distribution of the phos-
phatase in T84 cells. Therefore, we treated the cells with TNFa
for 72 h and performed immunofluorescence studies. PTPN2 was
equally distributed in the cytoplasmic and the nuclear
compartment of untreated control cells (figure 2A). While
PTPN2 in the nuclei was still equally visible compared with
control cells after 72 h TNFa treatment, the amount of PTPN2
in the cytoplasm had clearly increased (figure 2B). These findings
correlate with our protein data and support the hypothesis that
TNFa treatment not only increases PTPN2 protein levels, but
also causes a cytoplasmic accumulation of PTPN2 by 72 h
treatment.
PTPN2 protein is elevated in active CD
To demonstrate the relevance of these findings to human disease,
we performed immunohistochemical analysis of PTPN2 in
human colonic biopsy specimens from non-IBD patients, from
patients with clinically and macroscopically active CD or CD in
remission, from patients with clinically and macroscopically
active UC or UC in remission, as well as from patients with CD
responding to anti-TNF treatment. In non-IBD patients, only
low levels of PTPN2 protein were detectable (figure 3A). In
contrast, the epithelial layer of tissue specimens from patients
with active CD featured strong PTPN2 staining, indicating that
the protein is strongly expressed in IECs from patients with
active CD (figure 3B). Intestinal biopsy samples from patients
with CD in remission revealed similar PTPN2 protein levels to
those of control patients (figure 3C). Interestingly, while tissue
specimens from patients with active UC showed more PTPN2
staining than those from non-IBD control patients, PTPN2
protein levels in these samples were clearly less than in active
CD (figure 3D). Samples from patients with UC in remission
revealed levels of PTPN2 protein similar to control patients or
patients with CD in remission (figure 3E). Samples from
patients with CD in remission receiving anti-TNF treatment
revealed a staining intensity similar to samples from non-IBD
one control patients or from CD as well as UC patients in
remission (figure 3F). PTPN2 protein levels in the tissue samples
were then scored by a pathologist in a blinded manner. With this
approach we could fully confirm the visual observations, since
PTPN2 levels in samples from patients with active disease
reached a considerably higher score than in all of the other
groups. The score that was obtained by analysing samples from
CD patients in remission (with or without anti-TNF treatment)
was comparable with those obtained in samples from patients
with active UC or with UC in remission and slightly higher than
in non-control patients (figure 3G). These data correlate with
our previous PTPN2 mRNA findings in patient samples23 and
underline the relevance of our experiments for human disease.
TNFa increases PTPN2 protein via NF-kB activation
We next studied the mechanisms responsible for the effects of
TNFa on PTPN2. To investigate whether TNFa could mediate
its effects on the PTPN2 protein level via NF-kB, we stimulated
T84 cells with TNFa and/or the highly selective pharmacological
IKK inhibitor, BMS-345541 (25 mM), for 24 h. As shown by
representative western blots and densitometric analysis, TNFa
induced phosphorylation of IkBa (figure 4A) as well as of the
p65 subunit of NF-kB (figure 4B), while BMS-345541 alone or
in combination with TNFa suppressed IkBa (figure 4A) and
p65-NF-kB phosphorylation levels even below control values
(figure 4B). The same membranes as used in figure 4B were then
stripped and re-probed for PTPN2. TNFa elevated PTPN2
protein by 24 h of treatment (figure 4C). However, co-treatment
with BMS-345541 completely prevented the cytokine-induced
rise in PTPN2 protein (figure 4C). Representative western blots
of total IkBa (figure 4A) and of the loading control, b-actin
(figure 4C), show that the overall protein level in cells (co-)
treated with BMS-345541 was not altered. Since the amount of
cleaved caspase-3, a marker of apoptotic cell death, was not
altered under any conditions (figure 4D), these findings
demonstrate that the massive reduction in PTPN2 and p65-NF-
kB protein (figure 4B,C) was probably not due to cell death.
PTPN2 regulates TNFa-induced MAPK, but not NF-kB activation
To study whether PTPN2 could modify TNFa-induced signalling
in IECs, we performed PTPN2 knock-down studies using siRNA.
We transfected T84 cells with either non-specific siRNA or
PTPN2-specific siRNA constructs, and subsequently treated
these cells with TNFa for 24 h. TNFa treatment elevated
PTPN2 protein in T84 cells transfected with control siRNAwhile
PTPN2-specific siRNA caused a maximal decrease in PTPN2
protein of w75.565.1% (figure 5A). A representative western
blot of the loading control, b-actin, demonstrated that the
transfection procedure itself did not affect the overall protein
level in our cells (figure 5A). We then tested whether PTPN2
knock-down could affect the TNFa-induced activation of the
three MAPK isoforms, namely ERK1/2, p38 and JNK, as assessed
by their phosphorylation status. TNFa treatment increased the
phosphorylation of ERK1/2 in control siRNA cells, and loss of
PTPN2 potentiated this effect (figure 5B). Although TNFa alone
was not sufficient to induce the phosphorylation of p38 in cells
Figure 2 Tumour necrosis factor
a (TNFa) treatment causes cytoplasmic
accumulation of protein tyrosine
phosphatase N2 (PTPN2) in T84 cells.
Immunofluorescence microscopy of T84
cells shows PTPN2 staining in red and
nuclear staining in blue. Cells were (A)
either left untreated or (B) incubated
with TNFa (100 ng/ml) for 72 h. Each
panel shows representative images from
three similar experiments per condition.
Green arrows point to PTPN2 in the
nucleus, white arrows in the cytoplasm.
Orange line indicates 10 mM.
Magnification: 340.
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Figure 3 Protein tyrosine phosphatase N2 (PTPN2) protein is strongly expressed in intestinal biopsies from patients with active Crohn’s disease (CD).
Representative images of PTPN2 staining in intestinal biopsies derived from (A) non-inflammatory bowel disease (IBD) control patients (n¼11), (B)
patients with active CD (n¼16), (C) patients with CD in remission (n¼10), (D) patients with active ulcerative colitis (UC) (n¼11), (E) patients with UC
in remission (n¼10) and (F) patients with CD in remission responding to antitumour necrosis factor a (TNFa) treatment (n¼4) are demonstrated by
immunohistochemistry. Black arrows point to nuclear and white arrows to cytoplasmic PTPN2 protein in intestinal epitelial cells. Magnification:310 or
340 (enlargements), respectively. For AeE, tissue specimens from two different, representative patients are shown. (G) Histogram represents the
statistical analysis of PTPN2 protein levels in the immunohistochemically stained tissue samples as scored by a blinded pathologist. Asterisks indicate
significant differences compared with the score obtained by analysing the samples from non-IBD controls (***p<0.001).
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transfected with control siRNA, loss of PTPN2 permitted TNFa
to induce phosphorylation of p38 (figure 5C). In contrast,
neither TNFa treatment nor PTPN2 knock-down affected
the phosphorylation of JNK (figure 5D). Interestingly, while
TNFa induced phosphorylation of IkBa (figure 5E) as well as of
p65-NF-kB (figure 5F), these effects were not altered by PTPN2
knock-down (figure 5E,F). These findings demonstrate that
PTPN2 regulates the activation of the MAPK isoforms, ERK1/2
and p38, but not IkBa or p65-NF-kB in response to TNFa in
IECs.
Knock-down of PTPN2 potentiates the expression of
proinflammatory mediators
We next investigated whether PTPN2 might affect the expres-
sion and/or secretion of proinflammatory mediators in response
to TNFa treatment of T84 IECs. While TNFa induced the
secretion of the pleiotropic cytokine IL-6 into the supernatant of
T84 monolayers, this effect was further enhanced by PTPN2
knock-down (figure 6A). The concentration range of IL-6 in the
cell supernatant was between 0.130 and 3.615 pg/ml. Similarly,
loss of PTPN2 also potentiated the TNFa-induced secretion of
the proinflammatory IL-8 in our studies (figure 6B). The
concentration range was between 192 and 1,702 pg/ml. A
further important mediator of inflammation is iNOS, and
excessively elevated levels of iNOS have been found in the
intestine of patients with IBD.25 As expected, TNFa treatment
alone had no effect on iNOS protein (data not shown). Since
cytokine co-treatment is required to stimulate iNOS expres-
sion,26 we co-treated either control siRNA- or PTPN2 siRNA-
transfected cells with TNFa (100 ng/ml) and IFNg (100 ng/ml)
for 24 h. PTPN2-specific siRNA still caused a significant knock-
down of the phosphatase under these conditions (data not
shown). Although iNOS protein was not clearly elevated in
PTPN2-competent cells that had been co-treated with the
cytokine mix, loss of PTPN2 resulted in a significant increase in
iNOS protein in response to TNFa and IFNg co-treatment
(figure 6C). These data demonstrate that PTPN2 restricts the
TNFa-induced increase in the levels of proinflammatory medi-
ators and therefore regulates inflammatory responses in IECs.
DISCUSSION
We have previously shown that PTPN2 is activated by IFNg and
regulates intestinal epithelial barrier function.23 Here, we
demonstrate that PTPN2 is also upregulated by TNFa and
controls TNFa-induced signalling, cytokine secretion and
apoptosis. Both of these cytokines play important roles in the
pathogenesis of IBD, and of CD in particular. An impaired
epithelial barrier, dysregulated cytokine profiles and increased
levels of IEC apoptosis are well described pathological findings in
these diseases. Our studies revealed that all of these parameters
are critically regulated by the activity of PTPN2. These obser-
vations are aligned with studies of homozygous PTPN2-deficient
mice that feature elevated serum levels of IFNg and TNFa as
well as increased production of nitric oxide. These mice die
within 5 weeks of birth, suffering from a progressive systemic
inflammatory disease.27 28
With respect to TNFa induction of PTPN2 expression, we did
observe that PTPN2 mRNA expression showed a biphasic
increase in response to TNFa by 6 and 48 h. The first peak is
likely to be responsible for the increase in nuclear PTPN2 protein
after 24 h cytokine treatment, possibly causing dephosphoryla-
tion of nuclear signal transduction molecules. The latter peak
may account for the increased cytoplasmic PTPN2 protein in
response to 72 h TNFa. Since a certain amount of the nuclear
PTPN2 has translocated into the cytoplasm the second expres-
sion peak could serve to maintain a certain basal level of PTPN2
in the nucleus.
Of special interest with respect to human disease was the
finding that PTPN2 protein is strongly expressed in the intes-
tinal epithelium of patients with active CD, while PTPN2 levels
Figure 4 Tumour necrosis factor
a (TNFa) induces protein tyrosine
phosphatase N2 (PTPN2) protein via
nuclear factor-kB (NF-kB) in T84 cells.
(A) Representative western blots show
phosphorylated inhibitor of kBa (IkBa)
(Ser32) (above) and total IkBa (below)
after TNFa (100 ng/ml) and/or BMS-
345541 (25 mM) treatment for 24 h,
followed by densitometric analysis of
three similar experiments. (B)
Phosphorylation of the p65 subunit of
NF-kB (Ser536) (above) and protein
level of total p65-NF-kB (below) after
TNFa and/or BMS-345541 treatment
(24 h) are shown by representative
western blots of three similar
experiments and followed by
densitometric analysis. (C) Membranes
used in B were stripped and re-probed.
PTPN2 (above) and b-actin protein
levels (below) in TNFa- and/or BMS-
345541-treated cells (24 h) are shown
by representative western blots, and
densitometric analysis represents the
protein level of the respective proteins
(n¼3). (D) Representative western blots
of three similar experiments show
protein levels of full-length and cleaved caspase-3 in TNFa- and/or BMS-345541-treated cells (24 h). Asterisks indicate significant differences
compared with the respective control (*p<0.05; **p<0.01; ***p<0.001). #p<0.05; ###p<0.001 vs 24 h TNFa treatment.
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in tissue specimens from patients with CD in remission were
clearly lower than in samples from patients with active disease
and comparable with PTPN2 levels in non-IBD control patients.
These data suggest that PTPN2 expression might be critically
dependent on CD activity and correlate with the observation
that patients with active CD have higher serum levels of TNFa
than non-IBD patients,6 29 as well as with our in vitro data
showing that PTPN2 expression can be induced by TNFa. As
shown in figure 3D, intestinal biopsies from patients with active
UC had PTPN2 protein levels that were slightly higher than in
samples from non-IBD control patients, but lower than in
samples from patients with active CD. This finding suggests
that the upregulation of PTPN2 in CD might be somewhat
disease specific, since none of the samples from patients with
active UC showed PTPN2 levels that were comparable with
those observed in patients with active CD. One possible expla-
nation for this might be that patients with active CD present
with higher serum TNFa levels than patients with active UC.29
An NF-kB-binding motif has been described within the
PTPN2 promoter region.30 In our experiments NF-kB activity
regulates PTPN2 protein expression in response to TNFa, while
PTPN2 knock-down affected neither TNFa-induced IkBa nor
p65-NF-kB activation. The latter finding was somewhat
expected since NF-kB activation, and also IkBa activation,
occurs after phosphorylation of selective serine residues, while
PTPN2 only targets tyrosine residues. PTPN2 regulated the
TNFa-induced phosphorylation of the MAPK isoforms ERK1/2
and p38, both of which are activated, at least in part, by tyrosine
phosphorylation. These data are in good agreement with
a previous study from van Vliet et al, showing that PTPN2
regulates TNFa-induced MAPK signalling in monkey and mouse
fibroblasts.21 Taken together, these observations suggest that
PTPN2 plays an important role in maintaining the balance of
TNFa-induced signalling pathways. In particular, TNFa-medi-
ated NF-kB activity appears to restrict TNFa-induced MAPK
activity via the upregulation of PTPN2.
A large number of proinflammatory mediators are, at least in
part, regulated via the activity of MAPKs. Therefore, we spec-
ulated that loss of PTPN2 could alter the secretion of IL-6 and
IL-8, or the expression of iNOS, in T84 IECs in response to
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Figure 5 Protein tyrosine phosphatase N2 (PTPN2) knock-down enhances tumour necrosis factor a (TNFa)-stimulated extracellular signal-regulated
kinase 1/2 (ERK1/2) and p38 phosphorylation. T84 cells were transfected with either non-specific small interfering RNA (siRNA) or PTPN2-specific
siRNA and treated with TNFa (100 ng/ml) for 24 h. (A) Representative western blots for PTPN2 and b-actin followed by densitometric analysis of four
similar experiments. (B) Representative western blots and densitometry showing phosphorylation (Thr202/Tyr204) and protein expression of ERK1/2,
(C) phosphorylation (Thr180/Tyr182) and protein expression of p38, (D) phosphorylation (Thr183/Tyr185) and protein expression of c-Jun N-terminal
kinase (JNK), (E) phosphorylation (Ser32) and protein expression of inhibitor of kBa (IkBa) and (F) phosphorylation (Ser536) and protein expression of
the p65 subunit of nuclear factor-kB (NF-kB). Three similar experiments were performed for each protein. Asterisks indicate significant differences
compared with the respective control (*p<0.05; **p<0.01; ***p<0.001). ##p<0.01 vs 24 h TNFa treatment of control siRNA-transfected cells.
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TNFa. Our data demonstrate that TNFa induces the secretion
of both of these interleukins, and loss of PTPN2 potentiates this
effect. IL-6 is critically involved in the switch from innate to
adapted immune responses, since it regulates the recruitment of
leucocytes to sites of inflammation as well as the pattern of
infiltrating leucocytes into the acutely inflamed tissue.31 In
colonic biopsies from patients with active IBD, IL-6 levels
correlate with disease activity.32 Van Vliet et al demonstrated
increased secretion of IL-6 in TNFa-treated, PTPN2-deficient
mouse fibroblasts via elevated MAPK activity.21 These findings
are in good agreement with our data in IECs, showing that
PTPN2 knock-down results in increased p38 and ERK1/2 phos-
phorylation and, subsequently, in elevated IL-6 secretion in
response to TNFa.
It is well established that TNFa induces the secretion of IL-8
from IECs. Our data demonstrated that PTPN2 knock-down
further promotes the TNFa-induced secretion of IL-8. This
finding seems plausible since loss of PTPN2 results in increased
TNFa-mediated activation of ERK1/2 and p38. Both of these
MAPKs have been implicated in the secretion of IL-8 from IECs
in response to TNFa.33 Further, these data correlate with
observations seen in intestinal biopsies from patients with IBD
demonstrating elevated IL-8 levels in the intestinal mucosa.34
Excessive levels of nitric oxide as well as iNOS have been
demonstrated in the inflamed mucosa of patients with IBD.25
While low levels of nitric oxide seem to exert a protective effect
on the intestinal epithelium and intestinal barrier function, high
levels are clearly associated with progressive cell damage and
inflammation.35 These findings are consistent with our studies,
showing that TNFa and IFNg co-treatment caused a small, but
noteworthy, increase in iNOS protein, correlating with
a possible protective effect of moderate levels of iNOS during
inflammatory conditions. However, loss of PTPN2 permits the
cytokine mix to induce the expression of iNOS excessively,
a finding that can also be observed in IBD and that is associated
with more severe inflammation. These data, limited though they
are by extrapolation of in vitro cell studies to a complex human
disease, are at least consistent with our hypothesis that PTPN2
protects the intestinal epithelium and loss of PTPN2 results in
cell damage and higher levels of inflammation.
In summary, we have demonstrated that PTPN2 is activated by
TNFa and regulates TNFa-induced MAPK signalling. On a func-
tional level, loss of PTPN2 is associated with increased expression
and secretion of proinflammatory mediators. These proin-
flammatory events can be observed in the intestinal epithelium
of patients with IBD. Moreover, a mutation in the PTPN2
gene has been associatedwith IBD,while we have recently shown
that PTPN2 expression is elevated in active CD. We can speculate
that if the IBD-associated PTPN2 mutation causes a dysfunction
of the phosphatase in human colonic epithelial cells, then
expression of a dysfunctional PTPN2 mutant could result in
elevated activity of proinflammatory mediators and pathways in
the intestinal epithelium. Therefore, our data support a prelimi-
nary hypothesis that dysfunction of PTPN2 could make an
important contribution to the pathogenesis of IBD.
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